type I error rate and power for each vector of factor settings. We compare our results with two recently published NGS statistics. Also, we create a fictitious disease model based on downloaded 1000 Genomes data for 5 SNPs and 388 individuals, and apply our statistic to those data. We find that the LTT ae,NGS maintains the correct type I error rate in all simulations (differential and non-differential error), while the other statistics show large inflation in type I error for lower coverage. Power for all three methods is approximately the same for all three statistics in the presence of non-differential error. Application of our statistic to the 1000 Genomes data suggests that, for the data downloaded, there is a 1.5% sequence misclassification rate over all SNPs. Finally, application of the multi-variant form of LTT ae,NGS shows high power for a number of simulation settings, although it can have lower power than the corresponding single-variant simulation results, most probably due to our specification of multivariant SNP correlation values. In conclusion, our LTT ae,NGS addresses two key challenges with NGS disease studies; first, it allows for differential misclassification when computing the statistic; and second, it addresses the multiple-testing issue in that there is a multi-variant form of the statistic that has only one degree of freedom, and provides a single p value, no matter how many loci.
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Introduction
By now, it is well established that causal variants (CVs) will play an important role in disease gene mapping for complex traits. By CV, we mean an allele at a polymorphic locus that increases risk of acquiring a disease. Over the course of the last several decades, CVs have unquestionably played an important role in Mendelian diseases, i.e. diseases for which the probability of acquiring the disease conditional on having at least one copy of CV is large (near 100%) [1] .
One of the critical issues when applying statistical association methods with CVs is that of CV frequency (CVF). Mathematically, if a SNP locus has two variants, a (non-causal), and A (causal), the CVF equals Pr( A ) in the population. As computed using methods implemented in the programs Genetic Power Calculator [2] , CaTS [3] , and others, statistical power to detect association with a single CV when its frequency is very small (<0.01) and the genotype relative risks are moderate ( ≤ 2.0) is very low, for any fixed significance level and any 'reasonable' sample (say 1,000 cases, 1,000 controls). Equivalently, to achieve a statistical power of 80% for any fixed significance level requires an extremely large number of cases and controls (>10,000 each). For example, using the PAWE-PH website [4] , if the genotype relative risk of the heterozygote is 1.5, the disease mode of inheritance is multiplicative, the disease allele frequency is 0.01, and the SNP marker locus is the disease locus, then we require 13,926 cases and 13,926 controls to achieve 80% power at the 10E-4 significance level, even without phenotype misclassification.
Furthermore, the issue of misclassification of the CV call becomes extremely important. Several researchers have investigated the effects of genotype misclassification on the power and robustness of statistical association methods [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] . As documented by Kang et al. [24, 25] and Ahn et al. [26, 27] , and as can be illustrated using the method implemented in the PAWE software [28] among others, the limit of the 'cost' of genotype misclassification approaches infinity as the CVF approaches 0. Here, cost is defined as the ratio:
(Minimum sample size necessary to detect association in the presence of misclassification):(minimum sample size necessary to detect association when no misclassification is present).
In other words, when the CVF is small, even very small misclassification rates (say 1%) require prohibitively large sample sizes to detect association.
A number of statistical approaches have been proposed to deal with this situation [10, 11, 16, [29] [30] [31] [32] [33] [34] [35] [36] . A brief summary of findings is that there are two types of misclassification errors with which to be concerned; non-differential misclassification, in which error penetrances at a locus are the same in the affected and unaffected samples; and differential misclassification, in which penetrances differ among affected and unaffected samples. The former affects only statistical power in case-control association studies, but affects both power and type I error rate in family-based association. The latter affects type I error rates and statistical power even in case-control association studies.
A recent publication has looked at non-differential misclassification in NGS studies [37] . These authors found that even at very low error rates, misclassifying a common homozygote as a heterozygote causes (sometimes substantial) loss of statistic power to detect association, and this power loss grows as the minor allele frequency decreases. These results are consistent with the work by Kang et al. [24, 25] , who observed the same consequences for genotype misclassification.
From our perspective, differential misclassification error is more troublesome statistically, since one no longer knows the true null distribution and, therefore, true power cannot be determined.
One of the primary approaches for studying CVs is direct sequencing of the individuals of interest. In the past several years, the development of the next-generation sequencing (NGS) technology has made whole-exome (the protein-coding regions of a genome) or whole-genome sequencing an increasingly important component of medical genetic studies [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] . In addition to identifying disease-causing mutations (variants) in classic Mendelian inheritance disorders, the whole-exome/genome sequencing data has been used to identify CVs in complex diseases and 'orphan' diseases that occur in a very small number of individuals (e.g. Ng et al. [50] ). The wholegenome sequencing approach is particularly powerful when heterogeneity is present in the disease. For example, in a study of Kabuki syndrome, 32 different mutations were found in the MLL2 gene among the 53 families, including 12 de novo mutations [51] . Under this setting, the exceedingly low allele frequency of individual causal mutations makes misclassification a major problem. This documents the clinical importance of identifying very rare variants. The focus of our current work is an assessment of a new test statistic applied to more common variants (e.g. where the CVF is at least 1%). We provide more information in the Discussion.
Another issue affecting statistical power is that of multiple testing. Because the number of CVs observed will most certainly be larger than the number of common SNPs observed in any data set, any statistical procedure that tests all CVs must pay a larger 'penalty' in terms of correcting for multiple tests, thereby reducing power further. Several authors have considered the issue of multiple testing and have sought ways to address it in genetic studies [52] [53] [54] [55] [56] [57] . One solution is to determine the 'true' number of independent SNPs, so that the multiple testing correction is not as egregious. Ott and colleagues also worked on this problem [58] [59] [60] [61] [62] . Specifically, they considered the sums of single-locus statistics, and corrected for multiple testing through permutation. An advantage of this approach is that it incorporates the linkagedisequilibrium (correlation) structure among individual markers. Also, the sum statistic provides a single p value even though multiple markers are used, so no correction for multiple testing is necessary. This approach has also been incorporated in work by Purcell et al. [63] and Zhou and Pan [64] , among others.
In this work, we present a statistic based on the trend test developed by Cochran [65] and Armitage [66] . It is a likelihood ratio test in which the observed data are phenotype and NGS data, specifically the coverage and number of observed CV counts at one or more polymorphic non-synonymous coding SNPs. We note that work using the trend test for rare variants has already been published [67] . These authors found that in disease models with only rare risk variants, an statistical method based on the Cochran-Armitage trend test had power comparable to or greater than tests that pool (i.e. bin) rare variants. The authors concluded that efficient locus-wide inference using single-variant test statistics should be reconsidered as a useful framework for devising powerful association with rare-variant sequence data. As noted above, in this work we focus on slightly more common CVs.
Our statistic extends the work by Kinnamon et al. [67] in that it probabilistically estimates the true (unobserved) genotype based on the NGS data, and also estimates the sequence misclassification error probabilities in cases and controls (either separately or jointly). We evaluate the performance of our statistic on null and alternative data using simulations. We also use empirical 1000 Genomes SNP data to generate a fictitious disease phenotype, and apply our test statistic to such data to determine the p value and estimate of various parameters of interest.
Methods
We begin by providing some notation in table 1 . We follow with a description of the test statistic, simulations, and empirical data. 
The genotype frequency of the multi-locus genotype G t in the population. w G t = Weight corresponding to the multi-locus genotype G t . As above, we use dominant weight parameterization. Specifically:
. Note: as with the single-locus association situation, the mixing proportion in the case group is given by: , ,
, where conditioning is on the observed data x k .
log-Likelihoods and Computation of Test Statistic
Here, we present the log-likelihoods of the observed data, and we state the definition of the linear trend test allowing for errors applied to NGS ( LTT ae,NGS ) in terms of the log-likelihoods. 
is the maximum log-likelihood of the data for each hypothesis. This maximum is achieved by applying the EM algorithm in the following way: (1) Specify a certain number of starting points (i.e. randomly generated vectors ψ → of parameter settings for α , β , etc.).
(2) For each vector ψ → in item 1, update the log-likelihoods under each hypothesis until some stopping condition is satisfied, such as:
for some tolerance δ . In this work, we use δ = 0.00001. The maximum log-likelihood is then the ( r )-th step of ln( L H d ). We denote this value by
Note that for an arbitrary vector ψ → in item 1, if the stopping condition (eq. 1) is not met after the maximum number of steps, we define the log-likelihood as:
where r max is the total number of steps specified for the EM algorithm. For example, in the Simulations section below, r max = 1,000 (item xi). (3) We define the log-likelihood of the observed data, denoted ln( L H d ), as:
As noted above in item 3, the carat symbol ^ indicates that we have obtained the maximum loglikelihood of the data under the particular hypothesis. Note that LTT ae,NGS is asymptotically a χ 2 distribution with 1 degree of freedom. We design the LTT ae,NGS statistic to be robust to differential misclassification error among cases and controls, i.e. we specify ε t 0 ≠ ε t 1 .
Simulations
To evaluate the type I error rate and power of the test statistic under different scenarios, we perform simulations. In this section, we describe simulations where we consider type I error rate and power for a single CV. First, we simulate observed data for a single locus containing a CV for each individual based on their phenotype status. Next, we compute observed data for other loci based on a correlation coefficient.
The parameter settings that we consider for the first locus are: Under item iii, we specify that the disease locus is in Hardy-Weinberg equilibrium. Also, the genotype relative risk ( R 2 ) is defined in terms of the penetrances f i , 0 ≤ i ≤ 2 and the disease MOI. More specifically, f i = Pr (affected | i copies of the CV at a locus),
To determine genotypes at the remaining loci the LTT ae,NGS statistic for multiple loci, we use the correlation coefficient specified under item xv.
For any consecutive pair of loci, genotype frequencies (and thus CVFs) conditional on affection status are computed using the well-known correlation coefficient method for determining linkage disequilibrium. A full description is given in the online supplementary Appendix (for all online suppl. material, see www. karger.com/doi/10.1159/000346824).
For the null simulations, using parameter settings i-vii, and noting that disease MOI reduces to 1 MOI when R 2 = 1, we have a total of 96 simulation vectors. Also, for the alternative simulations, using the same parameter settings and noting that R 2 has only two values, we compute a total of 576 simulation vectors.
We compute the empirical power (see below for the H 0 term) at different significance levels (5%, 1%) for each of these settings by computing the LTT ae,NGS for each of the replicates listed under item xiii, determining the corresponding p value assuming a central χ 2 distribution with 1 degree of freedom under H 0 , and evaluating the proportion of replicates for which the p value is less than the corresponding significance level. When H 0 is true, we refer to the proportion as the empirical type I error rate for a given vector of parameter settings. When H 1 is true, we refer to the proportion as the empirical power for a given vector of parameter settings.
Comparison of the LTT ae,NGS Statistic with CMAT and SKAT Statistics
We compare our statistic with two other commonly used statistics that test for association with NGS data. They are: (a) the cumulative minor-allele test (CMAT) [69] , and (b) the sequence kernel association test (SKAT) [70] . We choose these statistics because: first, they test different components of a compound H 0 , as recently documented by Liu et al. (N. Tintle, pers. commun.; see Acknowledgements); second, computation is straightforward, so that we can easily program each statistic; and third, each has been well-cited (according to ISI Web of Science).
For the three statistics, we simulate CV count data for multiple loci in cases and controls. We use our statistic to determine (through the EM algorithm) the probabilities of each genotype at each locus. We use this information to determine the genotype probability calculations for SKAT and CMAT (see online suppl. Appendix). We compute empirical type I error and empirical power values as described above. We remove all individuals related to the probands of our data set, so that all individuals in our remaining data set are unrelated. Next, we download these unrelated individuals' sequenced raw file of exome alignment from the 1000 Genomes Project FTP site [72] . , , , , . For example, weight b 1 is -1.0, indicating that the CV is protective, which is contrary to our stated specification. Weights b 2 and weight b 3 are 0.5 and 0.0, respectively, which means they have little or no effect on disease risk. Weights b 4 and b 5 are rather large, suggesting that, if we find association, it is due to effects of SNPs 4 and 5. (3) We compute the median L k value over all 388 individuals. We define as 'affected' any individual whose L k value is above the median, and define as 'unaffected' any individual whose L k value is below the median. In this way, we obtain exactly 50% cases and 50% controls. Finally, we apply the LTT ae,NGS to this data set and compute significance, as well as parameter estimates.
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Results

Comparison of the LTT ae,NGS Statistic with CMAT and SKAT Statistics
Simulations under H 0 Here, we present results of the null simulations. Specifically, we report summary statistics for the empirical type I error rates with different settings of coverage ( v t k ). These results may be found in figure 1 (results presented in box and whisker plots [75] ). In this figure, the empirical type I error rates are computed only for the differential misclassification simulation settings ( One finding is immediate. The LTT ae,NGS statistic appears to maintain correct type I error rate for all coverage settings in the presence of differential misclassification. rs2274934  60897487  C  T  rs3737137  60897721  C  T  rs6143021  60897772  T  C  rs3810548  60905878  A  G  rs13042941 Note that, when the coverage is 3, the non-differential statistics have empirical type I error rates that are approximately 18 times the desired rate (0.05). More worrisome, from our perspective, is the fact that the median empirical type I error rates for these statistics are near 1.00, i.e. one would almost always reject the true H 0 if simulation settings are correct. When the coverage is 8, the non-differential statistics have empirical type I error rates that are approximately 7 times the desired rate (0.05). While the empirical type I error rates for this coverage are much closer to the 5% significance level, they still indicate substantial inflation in type I error. Only when the coverage rises to 25 do the empirical type I error rates for all three statistics appear to approximately equal to the 5% significance level. These results strongly suggest that, at lower coverage rates, not allowing for differential misclassification may result in a (sometimes substantial) increase in type I error for an NGS statistic. We note that a non-differential form of our LTT ae,NGS statistic produced similar inflation in empirical type I error to the CMAT and SKAT statistics (results not shown).
As previous research has documented [11, 26, 30, 36, [76] [77] [78] , when applying a statistic test that does not account for the potential differential genotype misclassification error, we observe an inflated empirical type I error rate. This makes sense because, unless we account for the differential errors in the analysis, the differential errors manifest themselves as a true phenotype-genotype association. Another question is raised by studying figure 1 : why is there substantial inflation in empirical type I error for lower coverage, but none observed for higher coverage? This question may be answered by observing that we specify the probability of the observed CV counts conditional on the underlying true genotype (and other parameters) as a binomial distribution (see online suppl. Ap- , and misclassification rate ε j t = 0.04. The probability of an observed count x k = 1 is 11% (we drop the m subscript from x to indicate we are considering data for a single variant). If we consider the heterozygote: j t = 1, the probability of an observed count x k = 1 is 37.5%. From these values, we see that it is somewhat difficult to determine with certainty the true underlying genotype. Now consider the values: v t k = 25, j t = 0 genotype, and misclassification rate ε j t = 0.04. The probability of an observed count x k = 1 is 37.5%. For the heterozygote: j t = 1, the probability of an observed count x k = 1 is 7.45E-05% (virtually 0). Also, for the j t = 2 genotype, the probability is 6.76E-31% (we would call this value 0). From these results, we would conclude with near certainty that the underlying genotype is j t = 0. Hence, even in the presence of misclassification error, higher coverage enables us to determine (much more precisely) the true underlying genotypes. It is for this reason that all three statistics maintain a correct type I error rate when v t k = 25. Finally, we note that, for the non-differential error simulations ( ε t 0 = ε t 1 ), all three statistics demonstrate correct empirical type I error rates at all coverages (results not shown). Therefore, we present empirical power results only for the non-differential settings.
Simulations under H 1 In table 3 , we present summary statistics of the empirical power differences (CMAT -LTT ae,NGS ) and (SKAT -LTT ae,NGS ) at the 5% significance level. Results are stratified by the disease MOI. Studying this table, we observe that the median and mean empirical power differences are close to 0 for nearly all disease MOI and statistics. Similarly, the mean differences are also close to 0.
Another observation is that the power differences are slightly skewed in favor of the CMAT and SKAT statistics. Specifically, the 3rd quartile values are all larger than the corresponding 1st quartile values for all rows. Having said this, we note that the minimum difference (in absolute value) is close to, if not greater than, the corresponding maximum value for each row, with the exception of the recessive disease MOI. We conjecture that power differences are 'more positive' for the recessive disease MOI because our statistic is really a 'dominant weight' statistic [79] , i.e. any multi-locus genotype containing at least one CV is given a weight of 1, and the only multi-locus genotype with a 0 weight is the one containing no CVs.
Because the empirical powers of the three methods are so similar, we focus on power results for our statistic. We run an analysis of variance (ANOVA) as implemented in the R software package [80] to determine what factors most significantly affect empirical power at the 5% level (results for the 1% significance level are nearly identical and therefore not shown). The factors we consider as input variables are items i-viii and xiv listed in the Methods section (under Simulations) and all two-way interactions. The response variable is the empirical power corresponding to the specific simulation vector. Note that, because the LTT ae,NGS statistic is robust to differential misclassification, we include empirical power results for differential error as well.
Here, we present just the terms of the ANOVA whose F statistic have a p value <2.00E-16 (full results not shown). In order of their F-statistic values (largest to smallest), the most significant factors are: (1) disease MOI All empirical powers were computed at the 5% significance level only for non-differential error simulations.
Trend To illustrate the importance of the first two factors (disease MOI and CVF) on empirical powers, we present a box and whiskers plot of the powers, stratified by settings for these two factors ( fig. 2 ) . Examining this figure, we observe that minimum, median, and maximum power can vary substantially, depending upon the disease MOI. For example, the minimum power for the dominant MOI is 0.5, when the CVF is 0.01. By contrast, the maximum power for the recessive MOI is 0.14, when the CVF is 0.05.
It is also reasonably clear that the CVF makes a difference when considering the disease MOI. For example, when the CVF is 0.01, the dominant MOI's most empirical powers range from 0.70 (1st quartile) to 1.00 (3rd quartile). By contrast, when the CVF is 0.05, power is virtually 1.00 for all other settings. Also, for the multiplicative MOI, when the CVF is 0.01, empirical powers range primarily from 0.20 (1st quartile) to 0.55 (3rd quartile).
However, when the CVF is 0.05, empirical powers increase so that the range is mostly 0.67 (1st quartile) to 0.99 (3rd quartile).
Genomes Data Example
When running the LTT ae,NGS on the 1000 Genomes data set, we obtain a test statistic value of 42.643, with a corresponding p value of 6.57E-11. The final parameter estimates are: = α = -13.144, β = 13.334, ε 0 = 0.017, ε 1 = 0.014, under H 1 . The genotype frequencies are not listed, since there are 243 such frequencies. The carat above each parameter indicates that this is a maximum likelihood estimate. It is interesting to note that the error values are independent of the fictitious disease model, i.e. it appears that there is an approximately 1.5% probability of misclassifying sequence data in the 1000 Genomes Project for these individuals and SNPs. Finally, we note that, for our disease model, the increase in risk of getting the disease is e (-13 .144 + 13.334) = 1.21 for any individual harboring a multilocus genotype with at least one CV. 
Summary and Discussion
The purpose of this work is to develop a linear trend test that can utilize phenotype and NGS data to perform a case-control genetic association analysis. As mentioned in the Introduction and documented in the online supplementary Appendix, our statistic probabilistically estimates the true (unobserved) genotype based on the NGS data, and also estimates the sequence misclassification error probabilities in cases and controls separately. Based on the results of simulations, our statistic appears to maintain the correct type I error rate in the presence of either differential or non-differential misclassification. Also, empirical power appears to be comparable to statistics such as the CMAT and SKAT statistics, depending upon the R 2 and CVF. One interesting result from the 1000 Genomes SNP data set is that our statistic estimates sequence misclassification errors of approximately 1.5% for the SNPs sequenced.
One of the key findings in this work is that the development of such a statistic is indeed possible; in the online supplementary Appendix, we present closed-form solutions of all necessary parameters. From this information, we may be able to extend the statistic to other models that are binary, in the sense that weights are either 0 or 1. We performed such computations for our linear trend test using double sampling [32] .
In previous research, we found that phenotype misclassification error has much larger effect, in terms of power loss, than genotype misclassification error. The one kind of genotype misclassification error that can be vexing is differential genotype misclassification. As noted in the Introduction, and as documented in our Results ( fig. 1 ) , differential genotype misclassification, even at low rates, can produce substantially inflated type I error rates [11, 26, 30, 36, 78] , so that the null distribution of the test statistic is no longer known. For that reason, we recommend that statistics like LTT ae,NGS be used when testing for association, or that already developed NGS statistics be modified to allow for differential misclassification. This recommendation is particularly important for designs with low coverage. In results not shown, even when error is non-differential, there is practically no power loss for the LTT ae,NGS statistic as compared with a non-differential form of the same statistic, so we suggest always using the statistic we report in this work. Such a suggestion is analogous to recommendations that one should use the H-LOD statistic (as compared with the LOD statistic) when performing linkage analysis, or that one should use the t test allowing for unequal variance as compared with the one that assumes equal variance in two groups; that is, these statistics are robust to some deviation from a common assumption (e.g. linkage homogeneity, equal variance) and there is very little power loss when using these statistics.
We are aware that the format of NGS data is evolving. The latest set of data from the 1000 Genomes Project has actual genotype calls along with quality scores. One of the nice features of likelihood-based methodology is that, as long as probabilities can be determined, statistics can be computed for multiple formats. We look forward to developing such statistics.
As mentioned in the Introduction, we are keenly aware of the clinical importance regarding identification of very rare variants. While the focus this work has been an evaluation of the LTT ae,NGS statistic applied to more common variants (1% ≤ CVF ≤ 5% for each CVF), we note that our statistic can handle any CVFs and determine accurate results. The reason is that the asymptotic distribution of the test statistic is more accurate as the number of loci considered is increased (irrespective of the CVFs), needing less reliance on permutation methods to compute significance. Also, our statistic was designed to handle multiple CVs, since increase in the number does not affect the degrees of freedom.
Is it possible to determine differential misclassification without the application of our statistic? We think so. In fact, we are aware of at least one paper [78] that looked at Q-Q plots to determine differential misclassification. If researchers have a sufficient number of polymorphic sites for which there is NGS data, we recommend using Q-Q plots. Another diagnostic test involves checking whether the missing rates among genomic sites differ between cases and controls [81] . While neither of these methods is definitive in determining differential misclassification (only double-sampling [82] can provide near-perfect evidence), results that deviate from expected results can be strongly suggestive. We note that not all researchers will perform either whole-exome or whole-genome NGS studies; some may perform candidate region studies with a relatively small number of sites tested. In those instances, Q-Q plots may not be as helpful, as they may not have a sufficient number of data points. In either situation, we comment that results from our simulations suggest that the LTT ae,NGS is robust to differential misclassification. Therefore, regardless of the nature of the misclassification, we anticipate that our statistic will provide valid results.
Along with the comments above, our statistic may be used in a confirmatory analysis for researchers who have found significant association with other methods. In this way, researchers can protect themselves from following up false positives.
Finally, we have developed an R version of the analysis software. In addition, we are developing a C version of the software for results using permutation testing. We plan to make these items available on the web by May 2013 to any interested researchers.
